The upcoming Samsung Galaxy Book 6 Pro and Galaxy Book 6 Ultra are now listed on the Bluetooth SIG database, a key step that ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for ...

It has been contended that the provision was enacted to safeguard the fundamental right of every child to free, fair and ...

The U.S. Navy will take delivery of new-build battleships, the largest ever built, in an announcement from President Trump in ...

The centerpiece of the Trump administration’s revamp of the U.S. Navy is the largest surface combatant America will build ...

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Pfizer is pursuing pipeline expansions through the Metsera acquisition and a major licensing deal with 3SBio. Find out why ...

Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.

Analyzing stochastic cell-to-cell variability can potentially reveal causal interactions in gene regulatory networks.

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...